Physician profile
Suzy Lee
NPI 1730185133
$1,029.81
in general payments reported to CMS, 2019-2025
14 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.38 · 2020: $348 · 2021: $116 · 2022: $131 · 2023: $84.46 · 2024: $91.34 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $256.55 | 2019-2025 | Xeomin |
| Galderma Laboratories, L.P. | $200.00 | 2020 | |
| Abbvie INC. | $119.20 | 2023-2025 | |
| Leo Pharma INC. | $97.50 | 2019-2020 | |
| Celgene Corporation | $72.73 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $43.63 | 2021-2022 | |
| Janssen Biotech, INC. | $41.50 | 2020-2021 | |
| Pfizer INC. | $41.18 | 2020-2021 | |
| Convatec INC. | $37.28 | 2023 | |
| Biofrontera INC. | $33.42 | 2020-2025 | Ameluz |
| Lilly USA, LLC | $27.91 | 2025 | Ebglyss, Taltz |
| Amgen INC. | $24.47 | 2022 | |
| Vyne Pharmaceuticals INC. | $20.35 | 2021 | |
| Revance Therapeutics, INC. | $14.09 | 2024 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzy Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.